These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Viral evasion of antigen presentation: not just for peptides anymore. Van Kaer L; Joyce S Nat Immunol; 2006 Aug; 7(8):795-7. PubMed ID: 16855602 [No Abstract] [Full Text] [Related]
10. Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation. Wiertz EJ; Devlin R; Collins HL; Ressing ME J Virol; 2007 May; 81(9):4389-96. PubMed ID: 17079308 [No Abstract] [Full Text] [Related]
11. Fibrocytes are potent stimulators of anti-virus cytotoxic T cells. Balmelli C; Ruggli N; McCullough K; Summerfield A J Leukoc Biol; 2005 Jun; 77(6):923-33. PubMed ID: 15767291 [TBL] [Abstract][Full Text] [Related]
12. [The biological function of the major histocompatibility complex]. López-Martínez A; Chávez-Muñoz C; Granados J Rev Invest Clin; 2005; 57(2):132-41. PubMed ID: 16524051 [No Abstract] [Full Text] [Related]
13. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates. Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of immune escape of cancer and its regulation. Morita R; Hirohashi Y; Torigoe T Rinsho Ketsueki; 2009 May; 50(5):375-80. PubMed ID: 19483397 [No Abstract] [Full Text] [Related]
15. Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Lilley BN; Ploegh HL Immunol Rev; 2005 Oct; 207():126-44. PubMed ID: 16181332 [TBL] [Abstract][Full Text] [Related]